Paris-based digital health startup Sim&Cure has landed €3 million in funding from Elaia and IT Translation. The company says that its product has already been used to treat more than 1,500 patients in 250 hospitals.
Founded in 2014, Sim&Cure is currently working on Sim&Size, a software suite that helps to treat brain aneurysm, which is an arterial malformation that involves one in 50 people in the world. The traditional treatment involves a neurovascular prosthesis, the size of which is not always optimal—in fact, it's oversized in 92 percent of cases, according to Sim&Cure.
The startup's software simulates each size and type of the prosthesis taking into account the patient's anatomy and allows choosing the best option, which supposedly decreases the probability of failure.
“During the last 2 years, we have demonstrated that Sim&Size could drastically improve patient care in Europe,” said Mathieu Sanchez, Sim&Cure CEO. “Our goal for the coming years is to duplicate the European model to the US and to facilitate the access to the software. We truly believe that Sim&Size could become a standard of treatment for cerebral aneurysm. We also plan to start a new R&D cycle to go further in securing the patient treatment by providing more reliable information to physicians prior to the surgery.”
ICYMI: Throughout May, tech.eu is focused on surfacing interesting stories, startups and people from the health/medtech industry, powered by Bayer G4A. With this program, the health industry giant aims to establish long-term partnerships with interesting digital health startups.
Would you like to write the first comment?
Login to post comments